Impact of HACOR Score on Noninvasive Ventilation Failure in Non-COPD Patients with Acute-on-Chronic Respiratory Failure

• Published in: Canadian respiratory journal 2021-07, Vol.2021, p.9960667-7
• Main Authors: Ding, Min, Han, Xiaoli, Bai, Linfu, Huang, Shicong, Duan, Jun
• Format: Article
• Language: English
• Subjects: Acidosis; Blood pressure; Care and treatment; Chronic obstructive pulmonary disease; Coma; Consciousness; Health status indicators; Heart beat; Heart rate; Hospitals; Humans; Hypoventilation; Intensive care; Intubation; Length of stay; Medical research; Medicine, Experimental; Mortality; Noninvasive Ventilation; Obesity; Oxygen therapy; Patients; Physiological aspects; Physiology; Pulmonary Disease, Chronic Obstructive - complications; Pulmonary Disease, Chronic Obstructive - therapy; Respiratory Distress Syndrome; Respiratory failure; Respiratory insufficiency; Respiratory Insufficiency - etiology; Respiratory Insufficiency - therapy; Respiratory Rate; Sleep apnea; Sleep apnea syndromes; Variables; Ventilators
• ISSN: 1198-2241; 1916-7245
• DOI: 10.1155/2021/9960667

Background. A rating scale that takes into account heart rate, acidosis, consciousness, oxygenation, and respiratory rate (the HACOR score) has been used to predict noninvasive ventilation (NIV) failure in patients with chronic obstructive pulmonary disease (COPD). However, the HACOR score has not been used to predict NIV failure in non-COPD patients with acute-on-chronic respiratory failure. Methods. This study was performed in the respiratory intensive care unit of a teaching hospital. Data had been collected prospectively between June 2011 and January 2019. We enrolled non-COPD patients who received NIV due to acute-on-chronic respiratory failure, pH 45 mmHg. NIV failure was defined as requiring intubation or dying during NIV. The HACOR score was determined at initiation and after 1-2, 12, and 24 h of NIV. Scores can range from 0 to 27, with higher scores indicating a higher risk of NIV failure. Results. A total of 148 patients were enrolled in the study, 52 with sleep apnea-hypopnea syndrome, 34 with chronic thoracic sequelae, 31 with bronchiectasis, 14 with chest wall deformity, 5 with obesity-hypoventilation syndrome, and 12 with other conditions. Of the patients, 19 (13%) experienced NIV failure. From initiation to 24 h of NIV, the HACOR scores of patients who experienced NIV failure were much higher than those of patients who received successful NIV. The area under the receiver operating characteristic curve was 0.69, 0.91, 0.91, and 0.94 when the HACOR score was tested at initiation and after 1-2, 12, and 24 h of NIV, respectively. To obtain the best sensitivity and specificity, the cutoff value at initiation was 7 with a sensitivity of 68% and a specificity of 61%. After 1-2 h of NIV, it was 5 with a sensitivity of 90% and a specificity of 85%. After 12 h of NIV, it was 4 with a sensitivity of 82% and a specificity of 91%. After 24 h of NIV, it was 2 with a sensitivity of 100% and a specificity of 76%. Conclusions. The HACOR score has high sensitivity and specificity for predicting NIV failure among non-COPD patients who receive NIV due to acute-on-chronic respiratory failure with respiratory acidosis.